Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) investors of a class action representing investors that bought securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"). Lifecore investors have until September 27, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attorn ...

CHASKA, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the Company will participate in the upcoming 17th Annual Barrington Research Virtual Fall Investment Conference. Lifecore management will participate in 1-on-1 investor meetings during the event, which is scheduled to take place virtually on Thursday, September 12, 2024. About Lifecore B ...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q4 2024 Earnings Conference Call August 27, 2024 8:30 AM ET Company Participants Stephanie Diaz - Vida Strategic Partners, IR Paul Josephs - President & CEO John D. Morberg - CFO & EVP Conference Call Participants Michael Petusky - Barrington Research Operator Greetings, and welcome to the Lifecore Biomedical Q4 and Full Year 2024 Earnings Call. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being rec ...

Exhibit 99.1 Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update -- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% -- -- High Value Pipeline Continues to Advance Toward Commercialization -- -- State-of-the-Art Technology Enhancements to Expand Capacity and New Business Opportunities – Conference Call Tomorrow Morning at 8:30 a.m. ET CHASKA, Minn., August 26, 2024 -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ...

-- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% -- -- High Value Pipeline Continues to Advance Toward Commercialization -- -- State-of-the-Art Technology Enhancements to Expand Capacity and New Business Opportunities – Conference Call Tomorrow Morning at 8:30 a.m. ET CHASKA, Minn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended May 26, 2024, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from _________ to _________. Commission file number: 000-27446 LIFECORE BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 94-3025618 ( ...

SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024. Lifecore operates as an integrated contract development and manufacturing organization in the U.S. and internationally. The Company purportedly designs, develops, manufactures, and sells differentiated products for biomaterial ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 22, 2024 (GLOBE N ...

SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024. Lifecore operates as an integrated contract development and manufacturing organization in the U.S. and internationally. The Company purportedly designs, develops, manufactures, and sells differentiated products for biomaterial ...

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. SO WHAT: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...